IL320556A - שיטות לטיפול במצבים דלקתיים - Google Patents

שיטות לטיפול במצבים דלקתיים

Info

Publication number
IL320556A
IL320556A IL320556A IL32055625A IL320556A IL 320556 A IL320556 A IL 320556A IL 320556 A IL320556 A IL 320556A IL 32055625 A IL32055625 A IL 32055625A IL 320556 A IL320556 A IL 320556A
Authority
IL
Israel
Prior art keywords
disease
peripheral
subject
compound
inflammatory condition
Prior art date
Application number
IL320556A
Other languages
English (en)
Original Assignee
Athira Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athira Pharma Inc filed Critical Athira Pharma Inc
Publication of IL320556A publication Critical patent/IL320556A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL320556A 2022-11-18 2023-11-17 שיטות לטיפול במצבים דלקתיים IL320556A (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263426620P 2022-11-18 2022-11-18
US202363447436P 2023-02-22 2023-02-22
US202363463742P 2023-05-03 2023-05-03
PCT/US2023/080224 WO2024108090A1 (en) 2022-11-18 2023-11-17 Methods of treating inflammatory conditions

Publications (1)

Publication Number Publication Date
IL320556A true IL320556A (he) 2025-07-01

Family

ID=89224259

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320556A IL320556A (he) 2022-11-18 2023-11-17 שיטות לטיפול במצבים דלקתיים

Country Status (8)

Country Link
EP (1) EP4618996A1 (he)
JP (1) JP2025538382A (he)
KR (1) KR20250110227A (he)
CN (1) CN120225201A (he)
AU (1) AU2023383348A1 (he)
IL (1) IL320556A (he)
TW (1) TW202432137A (he)
WO (1) WO2024108090A1 (he)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
AU2002303779A1 (en) * 2001-05-16 2002-11-25 Molecumetics, Ltd. Reverse-turn mimetics and methods relating thereto
AU2003284120A1 (en) * 2002-10-17 2004-05-04 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US20140094413A1 (en) 2012-04-02 2014-04-03 Washington State University Hepatocyte growth factor (hgf) mimics as therapeutic agents
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki
CA3196582A1 (en) 2020-11-02 2022-05-05 Leen Kawas Bicyclic compounds and uses thereof for the treatment of diseases
JP2025508768A (ja) * 2022-02-23 2025-04-10 アティラ・ファーマ・インコーポレイテッド Ｃｏｖｉｄ関連障害を処置する方法
US20250288587A1 (en) * 2022-05-04 2025-09-18 Athira Pharma, Inc. Methods of Treating Fibrosis
TW202406554A (zh) * 2022-05-04 2024-02-16 美商雅斯娜製藥公司 治療神經發炎性病況之方法

Also Published As

Publication number Publication date
JP2025538382A (ja) 2025-11-28
TW202432137A (zh) 2024-08-16
AU2023383348A1 (en) 2025-05-01
KR20250110227A (ko) 2025-07-18
EP4618996A1 (en) 2025-09-24
WO2024108090A1 (en) 2024-05-23
CN120225201A (zh) 2025-06-27

Similar Documents

Publication Publication Date Title
CA2400916A1 (en) Aminoadamantane derivatives as therapeutic agents
CA2528160A1 (en) Use of 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine for neuronal regeneration and functional recovery
EP4487916A3 (en) Ion channel modulators
MX2022013647A (es) Imidazopiridazinas como moduladores de il-17.
CA2438991A1 (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JP2003535094A5 (he)
AP2002002465A0 (en) Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or Vitamin E for the treatment of cognitive disorders.
RU2015112914A (ru) Бензимидазолы в качестве активных агентов для центральной нервной системы
RU2300373C2 (ru) Карбаматы для предотвращения или лечения нейродегенеративных нарушений
MX2025010188A (es) Moduladores farmaceuticamente activos de la nedilacion de culina mediada por dcn1/2 de tipo pirazolo-piridona
NZ512526A (en) 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
CA2171226A1 (en) Treatment of optic nerve disorder with prostanoic acid compounds
JP2019516756A5 (he)
IL320556A (he) שיטות לטיפול במצבים דלקתיים
CA2515590A1 (en) Pten inhibitor or maxi-k channels opener
CA2302347A1 (en) 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-oles, processes for their preparation and their use for medicaments
CA2414583A1 (en) Neuroprotective 7-beta-hydroxysteroids
WO2023235844A3 (en) Carbamoyl phenylalaninol compounds as taar1 agonists
CA2374997A1 (en) Il6ril6 chimera for the treatment of neurodegenerative diseases
MY121206A (en) Aminobenzamide compounds for the treatment of neurodegenerative disorders
WO2004014391B1 (en) Use of carboxamides for the treatment of tinnitus
RU2010117265A (ru) Способ лечения неврологических нарушений
CA2384690A1 (en) Rivastigmine for the treatment of ocular disorders
PH12015500059B1 (en) Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
CN213046928U (zh) 一种脑电波检测头套